Artivion Inc. Common Stock Q3 2025 Earnings Recap

AORT Q3 2025 November 7, 2025

Get alerts when AORT reports next quarter

Artivion delivered robust Q3 2025 results with constant currency revenue growth of 16% and adjusted EBITDA growth of 39%, driven by strong performance from stent grafts and On-X valves.

Earnings Per Share Beat

$0.16 vs $0.14 est.

+14.3% surprise

Revenue Miss

113388000 vs 116418570 est.

-2.6% surprise

Market Reaction

1-Day +0.25%

5-Day +1.85%

30-Day -1.47%

See AORT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Stent graft revenues surged 31% year-over-year, supported by the early adoption of AMDS, positioning it as a key growth driver.
On-X valves achieved a 23% revenue increase, benefiting from market share gains and the unique clinical advantages of the product.
The recent CMS reimbursement update for complex aortic procedures is expected to enhance the economic proposition of AMDS, further driving adoption.
Investment in expanded operational capacity in Austin, Texas indicates proactive measures to support anticipated growth in the On-X business.
Artivion maintains a strong pipeline of clinical evidence and promising early commercial traction across its product portfolio.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit AORT on AllInvestView.